Announcements Trials
Browse Landscape

Phase

Phase 1/2 4Phase 1 4Phase 2 2

Status

Recruiting 2Terminated 1Completed 1

Sponsor Class

INDUSTRY 4

Study Type

Interventional 4

Sponsor

Cancer Type

Lymphoid 4

Conditions

Lymphoma, Non-Hodgkin 4Lymphoma, B-Cell 4Lymphoma, Large B-Cell, Diffuse 3Lymphoma 2Recurrence 1Lymphoma, Mantle-Cell 1Immunoblastic Lymphadenopathy 1Ann Arbor Stage II Mantle Cell Lymphoma 1

Interventions

Cyclophosphamide 58Rituximab 54fludarabine 33fludarabine phosphate 32venetoclax 24Filgrastim 22Etoposide 18Bendamustine Hydrochloride 18Gemcitabine 17Peripheral Blood Stem Cell Transplantation 15Bortezomib 15Melphalan 14obinutuzumab 13Lenalidomide 12Dexamethasone 12Cytarabine 12Vincristine 11Vorinostat 10Tacrolimus 10Azacitidine 10pembrolizumab 9Prednisone 9Mycophenolic Acid 9Doxorubicin 9ibrutinib 8copanlisib 8Whole-Body Irradiation 8Radiotherapy 8Paclitaxel 8Interleukin-2 8

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Phase 1 × Lymphoma, Non-Hodgkin × glofitamab × Clear all
NCT05169515 2026-05-18

A Study Evaluating the Safety, Pharmacokinetics, and Efficacy of Mosunetuzumab or Glofitamab in Combination With CC-220 and/or CC-99282 in Participants With B-Cell Non-Hodgkin Lymphoma

Hoffmann-La Roche

Phase 1 Recruiting
121 enrolled
Lymphoid

Lymphoma, Non-Hodgkin

NCT06393738 2026-02-10

A Study of ARV-393 in Relapsed/Refractory Non-Hodgkin Lymphoma.

Arvinas Inc.

Phase 1 Recruiting
255 enrolled
Lymphoid

Immunoblastic Lymphadenopathy, Lymphoma, Non-Hodgkin, Recurrence, Lymphoma, B-Cell

NCT03467373 2025-01-17

A Study of Glofitamab in Combination With Rituximab or Obinutuzumab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (CHOP), or Polatuzumab Vedotin Plus Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone (CHP) in Participants With Non-Hodgkin Lymphomas or With DLBCL

Hoffmann-La Roche

Phase 1 Completed
111 enrolled
Lymphoid

Lymphoma, Non-Hodgkin, Lymphoma, B-Cell

NCT05219513 2024-08-23

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of RO7443904 in Combination With Glofitamab in Participants With Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma

Hoffmann-La Roche

Phase 1 Terminated
53 enrolled
Lymphoid

Lymphoma, Non-Hodgkin

Data powered by HemOnc (CC BY 4.0) Colophon âš¡